Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: INDI-702; NM-702; NT-702

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nissan Chemical Industries
  • Class Antiplatelets; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Thromboxane A2 synthase inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Asthma; Intermittent claudication

Most Recent Events

  • 12 May 2015 Nissan Chemical Industries terminates the license agreement with Taisho Pharmaceutical for parogrelil
  • 26 Aug 2009 Phase II development is still ongoing for intermittent claudication caused by arteriosclerosis obliterans in Japan
  • 26 Aug 2009 Discontinued - Phase II for intermittent claudication caused by spinal canal stenosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top